Forschung in Hamburg - ©
Im OP ©

Protembis Successfully Closed its Seed-Financing Round

Geratherm Medical AG and a group of angel investors will fund R&D and clinical trials of the Hamburg start-up

The Hamburg-based start-up Protembis GmbH has successfully closed a seven-digit seed financing round in order to fund R&D activities and clinical trials over the coming years. Protembis aims to develop, manufacture and commercialise an embolic protection device to be used during left heart procedures and vascular interventions. The ProtEmbo device is intended to protect patients from the risk of suffering a stroke during these procedures. In addition to the seed financing round, Protembis has secured a seven-digit state subsidy in co-operation with th Institute for Cardiovascular Engineering at RWTH University Aachen, which is granted by the Federal Ministry of Education and Research (BMBF). With the company’s locations in Hamburg and Aachen, opinion leaders, medical centres, funding and partner companies for product development, testing, feedback and commercialisation are easily accessible, which will enable Protembis to build a strong network of advisors and supporters for the development of its ProtEmbo device.

Next Steps

Dr. Gert Frank, CEO of Geratherm Medical AG, notes “The ProtEmbo device is clearly a novel and unique solution to address the danger of strokes in aortic valve replacement and other interventional heart procedures. Having closed this financing round Protembis will be able to reach the next level in terms of R&D and clinical trials. With Innovationsstarter Fonds Hamburg and the group of highly experienced angel investors we have an excellent setup to help further develop Protembis.”

Significant Milestones

Karl von Mangoldt and Conrad Rasmus, managing directors at Protembis GmbH, are pleased that the new investors provide a sound financing platform for the company’s future activities. They say: “This seed financing round allows us to achieve significant milestones in the development of our device and to obtain relevant clinical data.”
Along with the seed financing, Protembis has also strengthened its technical team. Oliver Schumacher, who has a wealth of experience with medical devices, will join the company as Chief Technology Officer.

source and further details:

About Protembis

Founded in autumn 2013, Protembis is a medical device start-up company headquartered in the vibrant Betahaus Hamburg, with an R&D base in the medical technology city of Aachen. The team’s vision is to bring its device into every interventional and surgical heart procedure, reducing the number of strokes and radically improving patient safety. Protembis GmbH is sponsored by the Federal Ministry of Education and Research.

About Innovationsstarter Fonds Hamburg

The “Innovationsstarter Fonds Hamburg” (innovation start-up fund Hamburg) invests in innovative, Hamburg-based companies to strengthen their research and development activities. The fund has an actual size of twelve million euro; capital is provided in equal share by the City of Hamburg and the European Regional Development Fund (EFRE). Innovationsstarter Fonds Hamburg GmbH, a fully owned subsidiary of IFB Hamburg, is entrusted with management of the fund.

More articles

  • There are no older articles in this category.
  • There are no newer articles in this category.